
Opinion|Videos|September 30, 2024
Acquired Resistance to Kinase Inhibitors - EGFR- mutated Non-Small Cell Lung Cancer
Author(s)Hatim Husain, MD
Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ongoing research into novel therapeutic strategies and combination approaches to overcome resistance mechanisms.
Advertisement
Episodes in this series

Now Playing
- Please discuss the issue of acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5




















